Drugs / LX107
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07063030 | Jul 2025 → Dec 2026 expected | inherited retinal dystrophy | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LX107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07063030 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “LX107 Gene Therapy” NCT07063030 ↗ |
| Route | Other | “Subjects will receive subretinal injection of LX107 on Day 0.” NCT07063030 ↗ |